Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Norris Perne & French LLP MI

Norris Perne & French LLP MI lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 29.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,401 shares of the medical research company's stock after selling 10,414 shares during the quarter. Norris Perne & French LLP MI's holdings in Thermo Fisher Scientific were worth $12,640,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in TMO. Cypress Advisory Group LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $253,000. Intact Investment Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after buying an additional 660 shares during the period. Purkiss Capital Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $1,121,000. LaFleur & Godfrey LLC grew its holdings in Thermo Fisher Scientific by 9.1% during the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock worth $15,486,000 after acquiring an additional 2,488 shares during the period. Finally, Deutsche Bank AG lifted its holdings in Thermo Fisher Scientific by 9.5% in the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after acquiring an additional 114,277 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $392.54 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The company has a market cap of $148.18 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.06 and a beta of 0.78. The company has a 50-day simple moving average of $414.12 and a 200-day simple moving average of $489.73. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the firm posted $5.11 EPS. Thermo Fisher Scientific's revenue was up .2% on a year-over-year basis. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.44%. Thermo Fisher Scientific's payout ratio is 10.09%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Barclays lowered their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Citigroup reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Royal Bank Of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $605.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.